Matches in Wikidata for { <http://www.wikidata.org/entity/Q91443804> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- Q91443804 description "article scientifique publié en 2018" @default.
- Q91443804 description "artículu científicu espublizáu n'agostu de 2018" @default.
- Q91443804 description "scientific article published on 01 August 2018" @default.
- Q91443804 description "wetenschappelijk artikel" @default.
- Q91443804 description "наукова стаття, опублікована в серпні 2018" @default.
- Q91443804 name "What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial" @default.
- Q91443804 name "What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial" @default.
- Q91443804 type Item @default.
- Q91443804 label "What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial" @default.
- Q91443804 label "What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial" @default.
- Q91443804 prefLabel "What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial" @default.
- Q91443804 prefLabel "What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial" @default.
- Q91443804 P1476 Q91443804-97C61438-68EC-4FDF-97DA-C594973D9C60 @default.
- Q91443804 P2093 Q91443804-0D4AC61D-7FC8-4CB6-BAC8-06735D414622 @default.
- Q91443804 P2093 Q91443804-1441A660-4BEF-4EA0-A6B3-061DE785F5E2 @default.
- Q91443804 P2093 Q91443804-59AC83C0-6A6D-4DA4-A759-6616AEDFCB76 @default.
- Q91443804 P2093 Q91443804-6900283E-81F4-4D8E-A8E2-FD290757E19F @default.
- Q91443804 P2093 Q91443804-7971B4A4-52F0-4D9E-9681-A73270087FB4 @default.
- Q91443804 P2093 Q91443804-827A18CD-3DB7-4340-AE95-08A4EE243A0B @default.
- Q91443804 P2093 Q91443804-B5EB85FC-145B-42A4-8D2B-87C512166035 @default.
- Q91443804 P2093 Q91443804-C6946649-7A5F-4A73-8026-77A8917851B8 @default.
- Q91443804 P2093 Q91443804-C924E938-1F69-4AC1-8FB2-79E9E355632A @default.
- Q91443804 P2093 Q91443804-DE8C3296-81E4-48FF-AEA1-70BAF9419319 @default.
- Q91443804 P2093 Q91443804-DFBA768B-ACB6-4215-BAFC-C6904990EF8E @default.
- Q91443804 P2093 Q91443804-E489A7ED-6E69-41BA-9FF6-684B35BE8242 @default.
- Q91443804 P2093 Q91443804-FD69EC34-DF7B-4CB7-9422-20554CE20475 @default.
- Q91443804 P275 Q91443804-0369a9c0-668b-41ea-89cc-106fdcc59164 @default.
- Q91443804 P304 Q91443804-834E8599-D04D-414B-982C-3847DD888B44 @default.
- Q91443804 P31 Q91443804-C1283415-A063-4142-B19C-AD685831202A @default.
- Q91443804 P356 Q91443804-59A2545E-94A9-4D3E-A75D-EF14DCE0982D @default.
- Q91443804 P433 Q91443804-FCEDDC0F-C020-47C6-AFCC-05BB81F3D540 @default.
- Q91443804 P478 Q91443804-ED740EF0-3643-4917-8AAE-6614AF4D945C @default.
- Q91443804 P50 Q91443804-F0188E36-8FF2-4DA6-9822-5AB12B9D9F64 @default.
- Q91443804 P577 Q91443804-31009CDC-7C5E-4255-8B68-FACA117D1AB9 @default.
- Q91443804 P6216 Q91443804-3a235e43-eec1-42de-9387-aa032f5095f9 @default.
- Q91443804 P698 Q91443804-376F49C7-9BDA-437F-8657-9DFF39ACEE3B @default.
- Q91443804 P932 Q91443804-B82E2D56-0DA8-4163-94A6-7E2F65191469 @default.
- Q91443804 P356 KCA-180038 @default.
- Q91443804 P698 30740581 @default.
- Q91443804 P1476 "What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial" @default.
- Q91443804 P2093 "Alastair Ritchie" @default.
- Q91443804 P2093 "Andrew Martin" @default.
- Q91443804 P2093 "Angela Meade" @default.
- Q91443804 P2093 "Benjamin Smith" @default.
- Q91443804 P2093 "Elizabeth Hovey" @default.
- Q91443804 P2093 "Ian D Davis" @default.
- Q91443804 P2093 "Martin R Stockler" @default.
- Q91443804 P2093 "Nicola J Lawrence" @default.
- Q91443804 P2093 "Prunella Blinman" @default.
- Q91443804 P2093 "Richard Kaplan" @default.
- Q91443804 P2093 "Shomik Sengupta" @default.
- Q91443804 P2093 "Simon Troon" @default.
- Q91443804 P2093 "Tim Eisen" @default.
- Q91443804 P275 Q34179348 @default.
- Q91443804 P304 "123-131" @default.
- Q91443804 P31 Q13442814 @default.
- Q91443804 P356 "10.3233/KCA-180038" @default.
- Q91443804 P433 "2" @default.
- Q91443804 P478 "2" @default.
- Q91443804 P50 Q79618528 @default.
- Q91443804 P577 "2018-08-01T00:00:00Z" @default.
- Q91443804 P6216 Q50423863 @default.
- Q91443804 P698 "30740581" @default.
- Q91443804 P932 "6364092" @default.